Repotrectinib - Bristol-Myers Squibb
At a glance
- Drug Originator TP Therapeutics
- Drug Licenced by ZAI Lab
- Drug Class Antineoplastics; Aza compounds; Fluorobenzenes; Ketones; Macrocyclic compounds; Pyrazoles; Small molecules
- Mechanism of Action Anaplastic lymphoma kinase inhibitors; Focal adhesion protein tyrosine kinase inhibitors; Janus kinase 2 inhibitors; ROS1 protein inhibitors; Src-family kinase inhibitors; TrkA receptor antagonists; TrkB receptor antagonists; TrkC receptor antagonists
- USA Patent Applicants BRISTOL
- USA Patents 5
- NDAs 1
- International Patents 125
- Patent Applications 290

Disclaimer